The pharmaceutical industry as an informant (Q34992767)

5 August 2017

1 reference

title

The pharmaceutical industry as an informant. (English)

1 reference

5 August 2017

Joe Collier

1

1 reference

5 August 2017

Ike Iheanacho

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

360

1 reference

5 August 2017

issue

9343

1 reference

5 August 2017

page(s)

1405-1409

1 reference

Publication bias: evidence of delayed publication in a cohort study of clinical research projects

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Source of funding and outcome of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Third generation oral contraceptives and risk of venous thrombosis: meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Industry-sponsored clinical research: a double-edged sword

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Evaluating drugs after their approval for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

What is meant by intention to treat analysis? Survey of published randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Report clears researcher who broke drug company agreement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Academia and industry: lessons from the unfortunate events in Toronto

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

1 reference

7 January 2021

Maintaining the integrity of the scientific record

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Sponsorship, authorship, and accountability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

No closure in sight for the 10/90 health-research gap

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Modulating the profit motive to meet needs of the less-developed world

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Failings in treatment advice, SPCs and black triangles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Sponsored journalism award shocks Australian media.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

Pharmaceutical branding of resident physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911394-8

7 January 2021

10.1016/S0140-6736(02)11394-8

Identifiers

DOI

1 reference

5 August 2017

1 reference